Last reviewed · How we verify
Rasagiline mesylate with Levodopa
Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while levodopa is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease.
Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while levodopa is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease. Used for Parkinson's disease (motor symptom management).
At a glance
| Generic name | Rasagiline mesylate with Levodopa |
|---|---|
| Sponsor | Teva Neuroscience, Inc. |
| Drug class | MAO-B inhibitor combined with dopamine precursor |
| Target | Monoamine oxidase B (MAO-B); Dopamine pathway |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Rasagiline selectively inhibits MAO-B, the enzyme responsible for breaking down dopamine, thereby prolonging dopamine availability in the striatum. Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase. Together, this combination maximizes dopamine levels to alleviate motor symptoms of Parkinson's disease.
Approved indications
- Parkinson's disease (motor symptom management)
Common side effects
- Dyskinesia
- Nausea
- Dizziness
- Headache
- Orthostatic hypotension
- Insomnia
Key clinical trials
- Azilect® In Wearing-Off (AIWO)
- Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China (PHASE3)
- A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness (PHASE1, PHASE2)
- Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China (PHASE3)
- Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea (PHASE3)
- Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations (PHASE3)
- Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa (PHASE3)
- A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rasagiline mesylate with Levodopa CI brief — competitive landscape report
- Rasagiline mesylate with Levodopa updates RSS · CI watch RSS
- Teva Neuroscience, Inc. portfolio CI